Avid Bioservices Inc (CDMO)

[Dragon Lady]

30 YEARS.."ANIMAL MODELS"..furry creatures, LOL !!

They are THIRTY FREAKING YEARS into this bad money pit w/ over 1/2 a $BA BILLION DOLLARS sunk into it....and they "PR" today about "PRE CLINICAL" testing in what....what......ANIMAL MODELS...LOL....oh gawd.

So...from..anyone remotely familiar w/ new drugs...knows that FURRY CREATURE "research" full of "we think" and "maybe" and it "appears to indicate"...and "could lead to"...might...maybe...possibly...blah, blah, blah means typically 8 to 10 YEARS MINIMUM on the "fast track" and typically $200 to $500 MILLION MINIMUM needed to ever get even a chance in hell at a phase III trial being conducted...really probably closer to $1 Ba BILLION dollars per reams of "think tank" published research, journalistic sources such as Forbes, and academia studies from Tufts and similar on new drug development costs and chances of new drug "lab candidates" ever, ever, ever reaching an actual FDA approval.

PPHM is back at "small clinical trials" and now LAB RATS and FURRY CREATURES, LOL !!

CARROTS...MORE DANGLING CARROTS...MORE CARROTS NEEDED...keep the gravy train alive and flowing....CARROTS....

https://www.google.com/search?q=dangling+carrots&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiYvPPTxfPPAhVBj1QKHT8tDGIQ_AUICCgB&biw=1280&bih=685#imgrc=qilnhLtPYQoW6M%3A

What's the "breast cancer market" in term of $dollars I wonder for helping mice, rats, pigs or dogs get "treated" for breast cancer? I'll have to Google those numbers today...see what the expected sales are gonna be, like in the next 6 fantasy months.

30 YEARS, 1/2 a $Ba BILLION in smoked up capital- and this mess still runs like they're a freaking start up, just born like last year or something.

Another PR about obscure "lab research" full of code-speak like "potential" and "seems to enhance" or whatever. They need MOUNTAINS OF CASH and YEARS, probably a DECADE to advance any of this....they're a tad late getting out of the starting gate looks like to me.

And NO, NO fantasy "big pharma" does deals or money-ball "partnerships" based on freaking "animal models"...not a chance in H IMO. DOES NOT HAPPEN...they want phase II/III drugs that have very high rates/chances of success...NOT PHASE III FUTILITY FAILERS.

Another big whoop "PR" looks like to me. Goose egg...not gonna move the needle is my guess.

ANIMAL MODELS...furry creature-ville....PRE CLINICAL...YEARS..YEARS:

"These study results provide the latest support for the belief that PS-targeting therapies can enhance the anti-tumor activity of checkpoint inhibitors such as anti-PD-L1 therapy in the treatment of TNBC. Just last month, we announced results from another preclinical study in TNBC demonstrating that 80% of animals receiving the triple combination of anti-PS, anti-PD-1 and anti-LAG3 therapies experienced complete tumor regressions, whereas there were no animals in the anti-PD-1 and anti-LAG3 combination treatment arm that had a complete regression,” said Jeff T. Hutchins, Ph.D., Peregrine’s vice president, preclinical research. “Additionally, these latest study findings related to increased PS expression on the surface of tumor cells following traditional cancer treatments demonstrate important activity within the tumor microenvironment that offers rationale for the potential of anti-PS agents in combatting cancer. We plan to continue to work with our collaborators at Duke University Medical Center to further study the therapeutic potential of PS-targeting agents in combination with checkpoint inhibitors like anti-PD-L1 and conventional therapies that augment immunotherapy mechanisms.”

Bavituximab is an investigational monoclonal antibody that targets PS. Signals from PS inhibit the ability of immune cells to recognize and fight tumors. Bavituximab is believed to override PS mediated immunosuppressive signaling by blocking the engagement of PS with its receptors as well as by sending an alternate immune activating signal. Previous studies demonstrated PS-targeting antibodies shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor responses. Peregrine evaluates the preclinical equivalent of bavituximab, ch1N11, in animal model studies to guide clinical development."